Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trials-Reference-Cited by-同舟云学术

Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trials

Published:2017-09-19 Issue:1 Volume:32 Page:244-248
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Piette C,Suciu S,Clappier E,Bertrand Y,Drunat S,Girard S,Yakouben K,Plat G,Dastugue N,Mazingue F,Grardel N,van Roy N,Uyttebroeck A,Costa V,Minckes O,Sirvent N,Simon P,Lutz P,Ferster A,Pluchart C,Poirée M,Freycon C,Dresse M-F,Millot F,Chantrain C,van der Werff ten Bosch J,Norga K,Gilotay C,Rohrlich P-S,Benoit Y,Cavé H

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2017289.pdf

Reference15 articles.

1. Avigad S, Kuperstein G, Zilberstein J, Liberzon E, Stark B, Gelernter I et al. TEL-AML1 fusion transcript designates a favorable outcome with an intensified protocol in childhood acute lymphoblastic leukemia. Leukemia 1999; 13: 481–483.

2. Rubnitz JE, Shuster JJ, Land VJ, Link MP, Pullen DJ, Camitta BM et al. Case-control study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: a Pediatric Oncology Group study. Blood 1997; 89: 1143–1146.

3. Vilmer E, Suciu S, Ferster A, Bertrand Y, Cave H, Thyss A et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Leukemia 2000; 14: 2257–2266.

4. De Moerloose B, Suciu S, Bertrand Y, Mazingue F, Robert A, Uyttebroeck A et al. Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): Report of the EORTC randomized phase 3 trial 58951. Blood 2010; 116: 36–44.

5. Domenech C, Suciu S, De Moerloose B, Mazingue F, Plat G, Ferster A et al. Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial. Haematologica 2014; 99: 1220–1227.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the gene fusion landscape in early onset sporadic rectal cancer reveals association with chromatin architecture and genome stability;Oncogene;2024-06-27

2. The Landscape of Secondary Genetic Rearrangements in Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia with t(12;21);Cells;2023-01-18

3. Fusion‐associatedcarcinomas of the breast: Diagnostic, prognostic, and therapeutic significance;Genes, Chromosomes and Cancer;2022-02-17

4. Prognostic Value and Outcome for ETV6/RUNX1-Positive Pediatric Acute Lymphoblastic Leukemia: A Report From the South China Children’s Leukemia Group;Frontiers in Oncology;2021-12-20

5. Genetic Alterations of Pediatric Acute Lymphoblastic Leukemia;Pediatric Acute Lymphoblastic Leukemia;2019-11-27